DateJuly 11th, 2019
PanTheryx partners with Zuellig Pharma to launch DiaResQ in Cambodia.
BOULDER, Colo.–(BUSINESS WIRE)–PanTheryx, a U.S. biotechnology company focused on addressing serious GI related health conditions, announced today the launch of DiaResQ in Cambodia through a partnership with Zuellig Pharma, a leading healthcare company in Asia.
DiaResQ is a nutritional intervention that contains immune factors, micronutrients, and macronutrients that work with the body to address the underlying cause of diarrhea. The product was recognized as one of the top 30 leading healthcare innovations that show promise to transform global health in Reimagining Global Health, Innovation Countdown 2030. The report is produced by PATH and supported by the Bill & Melinda Gates Foundation, US Agency for International Development and the Norwegian Agency for Development Cooperation.
With DiaResQ’s launch in Cambodia, clinicians now have access to a highly effective and clinically proven intervention for diarrhea, a disease that claims the lives of thousands of children in Cambodia each year.
“Core to our mission is to ensure that even the poorest and hardest to reach populations have access to diarrhea treatment,” said Scott Hyman, the Senior Vice President of PanTheryx, Inc. “Our partnership with Zuellig Pharma and the launch of DiaResQ in Cambodia is a true milestone for us as we work to fulfill that mission. We share a vision for the vast potential that nutritional interventions have to reduce the high number of deaths and enormous public burden due to diarrheal disease, improving the overall quality of life for families across Cambodia.”
Diarrhea is a leading killer of children, accounting for approximately 8 percent of deaths under age five worldwide. In Cambodia, pediatric diarrhea is the second leading cause of death in children under five. Many of these deaths could be avoided if access to proven prevention and management interventions were made routinely available to all Cambodian children.
In clinical trials, DiaResQ resolved a majority of cases of pediatric diarrhea after one day of use. No serious adverse events attributable to DiaResQ have been reported in its clinical trials that have collectively enrolled over 1,000 children and adults.
“We are thrilled to work in partnership with PanTheryx, and find much synergy in our mission to bring innovative healthcare solutions to those in need,” said Jean-Gaetan Guillemaud, General Manager at Zuellig Pharma. “We are confident that innovations such as DiaResQ will contribute to reducing child mortality and improve the health of many children in our country.”
Helping to facilitate the international partnership between Zuellig and PanTheryx is Michael Newbill, Chargé d’Affaires at the U.S. Embassy in Phnom Penh, Cambodia. Newbill said, “We are pleased to bring new therapies to Cambodia that can directly address the costs of diarrheal disease to this country and to so many around the world. PanTheryx is doing meaningful work and we appreciate their partnership and them bringing their products, research and knowledge to Cambodia.”
PanTheryx recently announced a new $50 million in financing round from Perceptive Advisors. With this funding, the company plans to expand DiaResQ into new countries to address diarrheal disease and to accelerate development of novel medical foods and biologics in its pipeline.
PanTheryx is a biotechnology company committed to realizing the potential of novel interventions to address a wide range of serious GI microbiome related health conditions. The company creates first-in-class therapeutics, with products developed from its patented technology platform spanning the range of nutritional interventions to biologics. PanTheryx is also the premier supplier of bovine colostrum, which has extensive applications in health and wellness, including GI health. Founded in 2007, PanTheryx is headquartered in Boulder, Colorado and has production facilities in Phoenix, AZ and Ripon, CA. For more information, please visit PanTheryx.com.
About Zuellig Pharma:
Zuellig Pharma is one of the largest healthcare services groups in Asia, driven by the purpose of making healthcare more accessible, providing world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started almost a hundred years ago and has grown to become a US$13 billion business covering 13 markets with over 10,000 employees. Its people serve over 350,000 medical facilities and work with over 1,000 clients, including the top 20 pharmaceutical companies in the world.
More recently, Zuellig Pharma has launched its Zuellig Health Solutions Innovation Centre to develop new services and address some pressing healthcare needs in Asia. Since then, its teams have been focused on creating data, digital and disease management solutions, supporting patients with chronic conditions and helping payors manage healthcare costs.
Holly Potter, Director